Evidence map›Paper›PMID 38125720›Full record

ArticleOncoimmunology2024

MHCII restriction demonstrates B cells have very limited capacity to activate tumour-specific CD4

Thomas V Guy, Alexandra M Terry, Helen M McGuire, Elena Shklovskaya, Barbara Fazekas de St Groth

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. B cells in cancer: functions, mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 3 countries.

Thomas V GuyT cell Biology Program, Centenary Institute of Cancer Medicine and Cell Biology, Sydney, NSW, Australia.ORCID 0009-0009-0383-4469
Alexandra M TerryT cell Biology Program, Centenary Institute of Cancer Medicine and Cell Biology, Sydney, NSW, Australia.
Helen M McGuireT cell Biology Program, Centenary Institute of Cancer Medicine and Cell Biology, Sydney, NSW, Australia.
Elena ShklovskayaT cell Biology Program, Centenary Institute of Cancer Medicine and Cell Biology, Sydney, NSW, Australia.
Barbara Fazekas de St GrothT cell Biology Program, Centenary Institute of Cancer Medicine and Cell Biology, Sydney, NSW, Australia.
Centenary Institute · AUThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There has been growing interest in the role of B cells in antitumour immunity and potential use in adoptive cellular therapies. To date, the success of such therapies is limited. The intrinsic capacity of B cells to specifically activate tumour-specific CD4+ T cells

Indexed as

Antigen-Presenting CellsNeoplasmsAnimalsB-LymphocytesCD4-Positive T-LymphocytesLymphocyte ActivationMiceAntigen presentationB cellMHC restrictionT celltumour

Identifiers

PMID38125720
PMCPMC10730170
OpenAlexW4389569126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.